Barchart.com
[[ type === 'moc' ? 'MARKET ON CLOSE' : 'FREE WEBINAR' ]]
[[ timeLabel ]] WATCH LIVE:
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Menu
Stocks | Futures | Watchlist | News | More
 
or
Watchlist | Portfolio | Dashboard
Site News
Contact
Market:
Faster, Cleaner, Better.
Menu

Zevra Therapeutics Inc (ZVRA)

Zevra Therapeutics Inc (ZVRA)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
News & Headlines for [[ item.sessionDateDisplayLong ]]
Notes
Alerts
Watch
Help
Go To:
Zevra Therapeutics to Present New Long-Term Real-World Data on MIPLYFFA® in Niemann-Pick Disease Type C (NPC) at the 2026 SSIEM Annual Symposium GlobeNewswire - Tue Aug 25, 6:30AM CDT

BOSTON, Aug. 25, 2026 (GLOBE NEWSWIRE) -- Zevra Therapeutics, Inc. (NasdaqGS: ZVRA) (Zevra, or the Company), a commercial-stage company focused on bringing life-changing therapeutics to people living...

ZVRA : 12.04 (+3.35%)
Zevra Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4) GlobeNewswire - Fri Aug 21, 3:30PM CDT

BOSTON, Mass., Aug. 21, 2026 (GLOBE NEWSWIRE) -- Zevra Therapeutics, Inc. (NasdaqGS: ZVRA) (Zevra, or the Company), a commercial-stage company focused on bringing life-changing therapeutics to people...

ZVRA : 12.04 (+3.35%)
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Zevra Therapeutics, Inc. - ZVRA PR Newswire - Thu Aug 13, 9:00AM CDT

NEW YORK , Aug. 13, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Zevra Therapeutics, Inc. ("Zevra" or the "Company") (NASDAQ: ZVRA). Such investors are advised...

ZVRA : 12.04 (+3.35%)
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Zevra Therapeutics, Inc. - ZVRA PR Newswire - Thu Aug 6, 10:02PM CDT

NEW YORK , Aug. 6, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Zevra Therapeutics, Inc. ("Zevra" or the "Company") (NASDAQ: ZVRA). Such investors are advised...

ZVRA : 12.04 (+3.35%)
Zevra Therapeutics: Q2 Earnings Snapshot AP - Wed Aug 5, 4:15PM CDT

Zevra Therapeutics: Q2 Earnings Snapshot

ZVRA : 12.04 (+3.35%)
Zevra Reports Second Quarter 2026 Financial Results and Corporate Update GlobeNewswire - Wed Aug 5, 3:05PM CDT

$39.7 million net revenue for Q2 2026, driven by $30.2 million in revenue from MIPLYFFA 53% increase in total net revenue over Q2 2025 Operational execution fueled strong cash position ...

ZVRA : 12.04 (+3.35%)
Zevra Therapeutics' Profit Streak Continues Tomorrow, But Revenue Growth Remains the Question Barchart - Tue Aug 4, 4:39PM CDT

Barchart Research What to Expect from ZVRA Earnings ZVRA Generated August 4, 2026 Current Price $10.52 EPS Estimate $$0.08 Consensus Rating Strong Buy Average Move 7.81% Zevra Therapeutics' Profit Streak...

ZVRA : 12.04 (+3.35%)
Zevra Therapeutics to Present at the Canaccord Genuity Annual Growth Conference GlobeNewswire - Tue Aug 4, 6:30AM CDT

BOSTON, Aug. 04, 2026 (GLOBE NEWSWIRE) -- Zevra Therapeutics, Inc. (NasdaqGS: ZVRA) (Zevra, or the Company), a commercial-stage company focused on bringing life-changing therapeutics to people living...

ZVRA : 12.04 (+3.35%)
Zevra Therapeutics (ZVRA) Securities Investigation Notice - Levi & Korsinsky PR Newswire - Mon Aug 3, 9:07AM CDT

Zevra investors who relied on public statements about arimoclomol's approval status faced losses after the July 24, 2026 negative opinion issued by the  European Medicines Agency's Committee for Medicinal...

ZVRA : 12.04 (+3.35%)
Zevra Therapeutics Announces Publication of Four-Year Real-World Data from U.S. Early Access Program Evaluating MIPLYFFA® (arimoclomol) in Niemann-Pick Disease Type C (NPC) GlobeNewswire - Mon Aug 3, 6:30AM CDT

BOSTON, Aug. 03, 2026 (GLOBE NEWSWIRE) -- Zevra Therapeutics, Inc. (NasdaqGS: ZVRA) (Zevra, or the Company), a commercial-stage company focused on bringing life-changing therapeutics to people living...

ZVRA : 12.04 (+3.35%)

Barchart Exclusives

Walmart Stock Is More Expensive Than Nvidia Amid Earnings Miss Barchart - 1 hour ago
Walmart stock slipped after its Q2 miss. Can its growth justify a sky-high valuation that touches the likes of Nvidia? Read more
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.